PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

NewsGuard 100/100 Score

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) have found a new therapeutic strategy for patients with a specific subtype of metastatic prostate cancer resistant to standard chemotherapy treatment with docetaxel.

In this study, published in the journal Frontiers in Pharmacology, they propose a new treatment based on a combination of kinase inhibitors in patients who inevitably stop responding to docetaxel. The team found that resistance to this drug is associated with the hyperactivation of the cellular pathways PI3K/AKT and MEK/ERK and have explored the possibility of inhibiting these pathways as a new therapeutic strategy in patients who maintain the function of PTEN, a negative regulatory protein of the PI3K/AKT pathway.

The results of the study have been satisfactory and, for this reason, the team wants to conduct a clinical trial to assess the safety and efficacy of this combination in patients with prostate cancer resistant to docetaxel. Vicenç Ruiz de Porras and Adrià Bernat-Peguera, ICO-IGTP researchers and co-first authors of the study, state that the results of this study "open the door to a new therapeutic strategy for those patients with PTEN wild-type tumors, who have progressed to docetaxel and in whom, unlike PTEN null patients, the efficacy of AKT inhibitors in monotherapy has not been demonstrated."

Source:
Journal reference:

Ruiz, V., et al. (2024). Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer. Frontiers in Pharmacology. doi.org/10.3389/fphar.2024.1331648.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts